Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923044 | 0.86 | KMT2A (0.70) | KMT2ACYP1A2CYP2C19LMNAL3MBTL1 | |
| SCHEMBL7311399 | 0.86 | KMT2A (0.70) | KMT2ACYP1A2CYP2C19LMNAL3MBTL1 | |
| SCHEMBL1585229 | 0.85 | PPARG (0.56) | KMT2ALMNAHDAC6 | |
| SCHEMBL30573531 | 0.85 | PPARG (0.56) | KMT2ALMNAHDAC6 | |
| SCHEMBL24529732 | 0.83 | KMT2A (0.53) | KMT2ACYP1A2CYP2C19LMNANSD2 | |
| SCHEMBL29723785 | 0.83 | KMT2A (0.53) | KMT2ACYP1A2CYP2C19LMNANSD2 | |
| SCHEMBL2735040 | 0.82 | KMT2A (0.87) | KMT2ACYP1A2CYP2C19LMNAL3MBTL1 | |
| SCHEMBL12505487 | 0.81 | KMT2A (0.63) | KMT2ACYP1A2CYP2C19LMNAL3MBTL1 | |
| SCHEMBL7317640 | 0.81 | MAPK8 (0.75) | KMT2ALMNAHPGD | |
| SCHEMBL27951599 | 0.80 | EGLN1 (0.64) | KMT2ACYP1A2CYP2C19LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937682-B1 | MET KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547782-B2 | Met kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| CN-101321751-A | Met kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-12-10 | — | — | CN | disclosed |
| WO-2007041379-A1 | MET KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078140-A1 | MET kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078140-A1 | MET kinase inhibitors | MET, ABL1, ERBB2 | KMT2A 365/4885CYP1A2 2556/4885CYP2C19 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.